Profile of BioIndustry Initiative sponsored TEMPO Delegation to SVOD

November 14-16, 2005 ● Palo Alto, California ● www.svod.org
Maria Douglass ● maria@douglass.com ● +1.703.298.1276

- TEMPO / Yuri Remnev
- AvaxisBio Inc. / Amir Maksyutov
- Biocad Ltd. / Dmitry Morozov
- Medical-biotechnological Center "Vector T" / Igor Timofeyev
- Inter-regional Immune Correction and Metabolic Therapy Institute (IMTP) / Vladislav Zhemchugov
- Research Company, Abercade / Nadezhda Orlova

www.biistate.net

TEMPO / Yuri Remnev

info@nptemp.ru : +7.095.708.3951 www.nptemp.ru

TEMPO (Technology, Education, Marketing, Production, and Optimization) is a Russian biotechnology consortium that unites seventeen leading biological research and production institutions. TEMPO was established in 2002 to bring together leading Russian research & development and manufacturing & sales organizations. The objectives of TEMPO include: developing innovative medical technology for commercialization; promoting the interests of the Russian biotechnology sector; partnering with western Industry and Academia; and diversifying funding sources for research and development.

AvaxisBio Inc. / Amir Maksyutov

amaksyutov@yandex.ru ●+7.383.336.6096

AvaxisBio

AvaxisBio, a biotechnology corporation established in 2004, focuses on design of novel polypeptide vaccines and therapeutics, based upon proprietary methodology. The founder of AvaxisBio, Dr. Amir Maksyutov, has developed a novel methodology to design chimeric peptide libraries, which mimic the diversity of antigenic variants of potentially protective hypervariable epitopes of viral proteins, and can induce a robust protective immune response to a wide range of existing and potential variants of the variable virus. Current vaccine platforms are inadequate at providing solutions for complex variable viruses. Vaxgen, the only company to advance to phase III clinical testing for an HIV vaccine, for example, announced in 2003 that no protection was observed. According to the

International AIDS Vaccine Initiative's 2004 Report, there are several major flaws with nearly all thirty, HIV vaccine candidates currently in early and late stage clinical trials. Similar problems confound the development of influenza and tuberculosis vaccines. AvaxisBio's vaccine methodology enables the development of vaccines against these moving targets by inducing *both protective humoral and cell-mediated responses to all existing and potential varieties of variable infectious agents*. AvaxisBio has successfully applied this technique to design a chimeric peptide library based on the V3 loop of gp120 of HIV-1 subtype B. This candidate peptide vaccine elicited pronounced humoral and cell-mediated immune responses to a wide range of HIV-1 variants in animal studies.

Biocad Ltd. / Dmitry Morozov

mdv@biocad.ru ● (095) 992 66 28 ● www.biocad.ru

Biocad aspires to become a leader in the field of biopharmaceuticals, focused on long-term development utilizing advanced achievements of science in cooperation with physicians. Biocad acquires and accumulates new knowledge that enables it to develop qualitatively new solutions to the problems of healthcare practitioners and create optimum conditions for maximizing quality of life for their patients. Biocad contributes to economic development of society, understanding, that it has the direct attitude to long-term health of our business. Opportunities for partnership include generic biopharmaceutical and active substance manufacture; novel, proprietary technology for scale-upable mammalian cell production; and novel, proprietary treatment of prostatisis, and other urogenital diseases demonstrated to cure acute infections in large scale clinical trials.

Medical-biotechnological Center "Vector T" / Igor Timofeyev

vector_ltd@ngs.ru ● +7.383.336.6204

The Medical-biotechnological Center "Vector-T" is a private company established in 2005 to organize of business on the basis of introduction of new high-technologies and know-how in the field of medicine and public health. M&BTC seeks protection for intellectual property and conducts the search for investment partners. Vector T's portfolio includes the following:

1. candidate anti-HIV microbicidal compounds and delivery system / gel for prophylaxis and treatment of sexually transmitted infections
2. physical mechanisms of the functioning of transport system in living organisms have been decoded. We have the 7 discoveries in this direction:

2.1. helical blood flow in the cardiovascular system
2.2. twisted flow of biological media in the transport
2.3. canals of cardiovascular, digestive, urinary-excretory, etc.
2.4. twisted liquid flow to create a tractive force in funnel-shaped canals
2.5. hemodynamics for arterial vessel canals
2.6. regularity of branching blood vessels in the blood circulation system
2.7. regularity of branching microvessels of the blood circulation system
2.8. acoustic field in the lumen of microvessels

Inter-regional Immune Correction and Metabolic Therapy Institute (IMTP) / Vladislav Zhemchugov

zhem-wlad@mtu-net.ru ● +7.095. 996.1032

Tularemia bacterium is on top of the list of infectious agents of serious concern. Tularemia outbreaks have been registered in Kosovo, Spain, Slovakia, Central part of Russia and Martha's Vineyard (USA) over the past 5 years. Available live tularemia vaccine («LVS» – USA) is highly reactogenic, unstable in production and storage. "C"-complex based subunit tularemia vaccine has obvious advantages over the live vaccine, mostly due to its safety, and the possibility of oral administration in combination with anti-bacterial drugs. IMTP has developed a technology for extracting and purifying the external "C"-complex of the tularemia bacterium – RF patent # 2221591, 2003. The "C"-complex drug prevents white mice from dying when they are subcutaneously infected with type B *F. tularensis* (10^2 live microbe cells). Moreover, the "C"-complex is protective for white mice when subcutaneously challenged with type A *F. tularensis* (10^2 live microbe cells).

Research Company, Abercade / Nadezhda Orlova

Abercade, founded in 1999, is one of the leading companies in the area of development of innovation projects. Abercade formulates and implements comprehensive business development programs including detailed sector and market studies, organizational consulting programs and development of and support to venture financing schemes. It also arranges marketing events. Abercade conducts regular research into industrial sectors and markets. Emphasis is laid on the analysis of industrial markets since this area is hardly studied at all. This is especially true of high-tech industrial sectors such as the biotechnology. Abercade takes an integrated approach to the study of industrial markets. In each market we analyze the entire succession of production chain,

starting with primary materials and ending with the finished products as well as all types of equipment and auxiliaries used in the sector. This approach permits Abercade to form a holistic and detailed concept of key trends and market forces at play, apart from collecting primary market data.